Evidence map›Paper›PMID 36961677›Full record

ArticleClinical and experimental medicine2023

miR-146a-3p as a potential novel therapeutic by targeting MBD2 to mediate Th17 differentiation in Th17 predominant neutrophilic severe asthma.

Wentao Duan, Jin Huang, Binaya Wasti, Zhifeng Chen, Yu Yuan, Yi He, Danhong Li, Jingsi Jia, Shaokun Liu, Yi Liu and 6 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical and experimental medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
3.3field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 19 citations in OpenAlex.

  1. Article
  2. Review
  3. Lp-PLA2-derived LysoPC drives dendritic cell immunogenic activation and Th17 inflammation in severe asthma.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2026
    Article
  4. Review
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. miRNAs as Modern Biomarkers in Asthma Therapy.International journal of molecular sciences · 2023
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 8 institutions in 1 country.

Wentao DuanDepartment of Respiratory and Critical Care Medicine, The Second Xiangya Hospital, Central South University, Changsha, 410011, China.
Jin HuangChangsha Social Work College, Changsha, 410004, China.
Binaya WastiDepartment of Respiratory and Critical Care Medicine, The Second Xiangya Hospital, Central South University, Changsha, 410011, China.
Zhifeng ChenDepartment of Respiratory and Critical Care Medicine, The Second Xiangya Hospital, Central South University, Changsha, 410011, China.
Yu YuanDepartment of Respiratory and Critical Care Medicine, The Second Xiangya Hospital, Central South University, Changsha, 410011, China.
Yi HeDepartment of Respiratory and Critical Care Medicine, The Second Xiangya Hospital, Central South University, Changsha, 410011, China.
Danhong LiDepartment of Respiratory and Critical Care Medicine, The Second Xiangya Hospital, Central South University, Changsha, 410011, China.
Jingsi JiaDepartment of Emergency, The Second Xiangya Hospital, Central South University, 139 Middle RenminRoad, 410011, Changsha, China.
Shaokun LiuDepartment of Respiratory and Critical Care Medicine, The Second Xiangya Hospital, Central South University, Changsha, 410011, China.
Yi LiuDepartment of Respiratory and Critical Care Medicine, Zhuzhou City Central Hospital, Zhuzhou, 412007, China.
Libing MaDepartment of Respiratory and Critical Care Medicine, The Affiliated Hospital of Guilin Medical College, Guilin, 541001, China.
Qingping ZengDepartment of Respiratory and Critical Care Medicine, Longshan County People's Hospital, Longshan, 416800, China.
Liming ZhuDepartment of Respiratory and Critical Care Medicine, Hunan Provincial People's Hospital (The First-Affiliated Hospital of Hunan Normal University), Guhan Road No. 89, Changsha, 410016, China. zhuliming3298@163.com.
Jianmin LiDepartment of Respiratory and Critical Care Medicine, Hunan Provincial People's Hospital (The First-Affiliated Hospital of Hunan Normal University), Guhan Road No. 89, Changsha, 410016, China. 38918007@qq.com.
Xiufeng ZhangDepartment of Respiratory Medicine, The Second Affiliated Hospital of Hainan Medical College University, 570000, Haikou, China. zxf96178@126.com.
Xudong XiangDepartment of Emergency, The Second Xiangya Hospital, Central South University, 139 Middle RenminRoad, 410011, Changsha, China. xudongxiang@csu.edu.cn.
Central South University · CNSecond Xiangya Hospital of Central South University · CNAffiliated Hospital of Guilin Medical College · CNChangsha University · CNHainan Medical University · CNHunan Normal University · CNHunan Provincial People's Hospital · CNZhuzhou Central Hospital · CN

Funding

National Natural Science Foundation of China 81960006National Natural Science Foundation of China 82170039Suitable Technology promotion project of Hunan Provincial Health Commission WP2020-4
6 · The paper itself

Abstract

Th17 (T-helper 17) cells subtype of non-T2 (non-type 2) asthma is related to neutrophilic infiltration and resistance to inhaled corticosteroids (ICS), so is also known as severe asthma. Methyl-CpG binding domain protein 2 (MBD2) regulates the differentiation of the Th17 cells, tending to show a therapeutic target in severe asthma. miR-146a-3p is associated with anti-inflammatory characteristics and immunity. Moreover, bioinformatic analysis showed that MBD2 may be a target gene of miR-146a-3p. However, the role of miR-146a-3p in the differentiation of Th17 cells via MBD2 in severe asthma remains unknown. Here, we aimed to explore how miR-146a-3p interacts with MBD2 and affects the differentiation of Th17 cells in severe asthma. First, we recruited 30 eligible healthy people and 30 patients with severe asthma to detect the expression of miR-146a-3p in peripheral blood mononuclear cells (PBMCs) by qRT-PCR. Then, we established a HDM/LPS (house dust mite/lipopolysaccharide) exposure model of bronchial epithelial cells (BECs) to evaluate the expression of miR-146a-3p, the interaction between miR-146a-3p and MBD2 using western blot and luciferase reporter analysis and the effect of miR-146a-3p regulated Th17 cells differentiation by flow cytometry in BECs in vitro. Finally, we constructed a mouse model of Th17 predominant neutrophilic severe asthma to assess the therapeutic potential of miR-146a-3p in severe asthma and the effect of miR-146a-3p regulated Th17 cells differentiation via MBD2 in vivo. Decreased miR-146a-3p expression was noted in severe asthma patients, in the BECs and in the animal severe asthma models. Moreover, we demonstrated that miR-146a-3p suppressed Th17 cells differentiation by targeting the MBD2. miR-146a-3p overexpression significantly reduced airway hyperresponsiveness, airway inflammation and airway mucus secretion, while also inhibiting Th17 cells response in vivo, which relieved severe asthma. By targeting MBD2 to suppress Th17 cells differentiation, miR-146a-3p provides a potential novel therapeutic for Th17 predominant neutrophilic severe asthma.

Indexed as

AsthmaMicroRNAsAnimalsCell DifferentiationDNA-Binding ProteinsHumansLeukocytes, MononuclearMiceTh17 CellsDNA-Binding ProteinsMBD2 protein, humanMbd2 protein, mouseMicroRNAsMIRN146 microRNA, humanMirn146 microRNA, mouseMBD2miR-146a-3pSevere asthmaTh17

Identifiers

PMID36961677
PMCPMC10543568
OpenAlexW4360804105

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.